Market Insight - Rare diseases and changes for the common good
This article was originally published in Scrip
An orphan medicinal product is defined as a product to treat life-threatening or serious debilitating conditions for which no, or no satisfactory, alternative exists. The current EU definition of rare diseases is a prevalence of less than five cases per 10,000 persons. The European Union Orphan Medicinal Product (OMP) Regulation was introduced in 2000 with the remit of providing timely and equitable access to therapies for patients with rare diseases, and to balance risk by providing economic and other incentives to industry to develop such therapies.
You may also be interested in...
One year after acquiring Piramal's Domestic Formulations business in a deal that made it India's largest pharmaceutical player, Abbott remains confident about its growth prospects in India, where it hopes to be generating $2.5 billion in sales by 2020. But facing fierce competition from domestic firms, Abbott isn't about to get complacent, Michael Warmuth, senior VP of the company's Established Products Division, tells Pete Chan. This article is part of the 2011 Scrip Asia 100.
Asia life science-focused VC firms*
Roche is overhauling its cost structure to produce a leaner organisation better equipped to focus on the business of pharmaceutical innovation. It is also investing heavily in China, turning its Shanghai operations into a centre for everything from commercial manufacturing and research to partnering, licensing and strategic planning. Pascal Soriot, chief operating officer of Roche Pharmaceuticals, speaks to Pete Chan in an exclusive interview.